RCUS - Arcus Biosciences, Inc.

NYSE - NYSE Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual
Subscribe to Premium to download historical data

Income Statement

All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Premium.Learn more
Breakdown
ttm
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Total Revenue
15,000
15,000
8,353
1,413
0
Operating Expense
113,336
103,709
63,212
54,854
18,182
Operating Income
-98,336
-88,709
-54,859
-53,441
-18,182
Net Non Operating Interest Income Expense
4,314
5,201
4,922
359
212
Other Income Expense
-
-1,202
343
-
-
Pretax Income
-94,793
-84,710
-49,594
-53,082
-17,970
Net Income Common Stockholders
-94,793
-84,710
-49,594
-53,082
-17,970
Diluted NI Available to Com Stockholders
-94,793
-84,710
-49,594
-53,082
-17,970
Basic EPS
-
-
0.0014
-0.0022
0
Diluted EPS
-
-
0.0014
-0.0022
0
Basic Average Shares
-
-
34,618
24,555
24,555
Diluted Average Shares
-
-
34,618
24,555
24,555
Total Operating Income as Reported
-98,336
-88,709
-54,859
-53,441
-18,182
Total Expenses
113,336
103,709
63,212
54,854
18,182
Net Income from Continuing & Discontinued Operation
-94,793
-84,710
-49,594
-53,082
-17,970
Normalized Income
-95,275
-84,710
-50,823
-53,082
-17,970
Interest Income
4,314
5,201
4,922
359
212
Net Interest Income
4,314
5,201
4,922
359
212
EBIT
-98,336
-88,709
-54,859
-53,441
-18,182
EBITDA
-94,869
-
-
-
-
Reconciled Depreciation
3,467
3,578
3,664
2,612
1,314
Net Income from Continuing Operation Net Minority Interest
-94,793
-84,710
-49,594
-53,082
-17,970
Total Unusual Items Excluding Goodwill
482
0
1,229
-
0
Total Unusual Items
482
0
1,229
-
0
Normalized EBITDA
-95,351
-85,131
-52,424
-50,829
-16,868
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0